Pharma
Commented by Fabian Lorenz on January 16th, 2026 | 07:05 CET
First Majestic reports, but the stock fails to benefit! Bayer continues to rise! Silver Viper takes off!
The upward trend in silver remains fully intact, and clear triple-digit price targets are circulating through the market. Yesterday, core holding First Majestic Silver reported on the fourth quarter and full year 2025. However, the stock failed to benefit from the news. Investors may find better opportunities in 2026 with Silver Viper shares. The silver explorer is undergoing a transformation and now holds three projects in Mexico. The most recent capital increase was met with strong demand, and drilling programs and results are expected in the current year. Looking at the share price chart of Bayer, one might think that the Leverkusen-based company had struck silver. The share price rose sharply in the first few days of the new year. However, analysts believe the upside potential has largely been exhausted.
Read
Commented by Nico Popp on January 14th, 2026 | 07:20 CET
Targeting cancer metabolism: Why Bayer and Pfizer are restructuring - and why Vidac Pharma is filling a scientific gap
The investment year 2026 marks a decisive turning point for the global biotechnology and pharmaceutical sector. After a period of macroeconomic uncertainty, we are witnessing a renaissance in the life sciences, driven by two fundamental forces: the urgent need for big pharma players to replace their expiring patents with innovation, and the scientific breakthrough of novel mechanisms of action in agile biotech small caps. While industry giants such as Pfizer and Bayer are attempting to steer their cumbersome tankers onto a new course through massive restructuring, the as-yet little-noticed biotech company Vidac Pharma is delivering the technological innovation the market is looking for. With an approach that directly addresses cancer metabolism and reverses the "Warburg effect," which has been known for almost a century, Vidac is positioning itself as a disruptive force in oncology and dermatology. For investors, this constellation offers a rare opportunity: to observe the stability of the giants while betting on the explosive potential of a technological innovator that analysts say is massively undervalued.
Read
Commented by Armin Schulz on January 8th, 2026 | 07:05 CET
How to benefit from the healthcare industry's comeback in 2026: Novo Nordisk, Vidac Pharma, and Pfizer in focus
After a disappointing year for investors in the pharmaceutical and biotech industries, the tide is now turning decisively on the stock market for these stocks. Political clarity, a return to major acquisitions, and groundbreaking clinical data are laying the foundation for a sustainable comeback. This new optimism is opening up concrete opportunities for strategic investments. Three companies exemplify these promising drivers: Novo Nordisk, Vidac Pharma, and Pfizer.
Read
Commented by André Will-Laudien on January 2nd, 2026 | 07:05 CET
Attention - fasten your seatbelts! 2026 could be a rocket launch for Novo Nordisk, Evotec, Bayer, and Vidac Pharma
The stock market is starting the new year 2026 in a buoyant mood. The mining and commodities sector showed that it is not only possible to make money with tech stocks, with almost every stock doubling in value, and some even increasing tenfold. The coming year, however, could bring yet another shift in perspective. The biotech sector has been quiet for quite some time, but some of the protagonists in our selection are showing, in part, significant technical base formations. For risk-aware investors, it may be time to reshuffle more decisively and realign portfolios. Come in and find out!
Read
Commented by Carsten Mainitz on December 23rd, 2025 | 08:45 CET
USD 600 billion market potential – Pfizer and Bayer are in the race, Vidac Pharma in the fast lane?
The market for cancer drugs is the largest segment within the pharmaceutical industry and currently has a volume of over USD 200 billion. According to experts, the market will already be worth USD 500 to 600 billion by 2032 or 2033. Companies such as Pfizer and Bayer are among the industry leaders. As is often the case, however, there are promising stocks from the second and third tiers beyond the blue chips. One such company is Vidac Pharma. The Company is pursuing a new, promising approach to skin cancer. Analysts attest to the shares' great potential.
Read
Commented by Armin Schulz on December 17th, 2025 | 07:05 CET
How Bayer, WashTec, and Volkswagen will earn more money in the future with digitalization and AI
Artificial intelligence is already generating measurable profits in industry today. In the pharmaceutical and chemical industries, it is revolutionizing research and accelerating the market launch of vital products. Mechanical and plant engineering is tapping into recurring sources of revenue with AI-based services and strengthening customer loyalty. And in the automotive industry, autonomous driving is highly popular and will shape the future. These advances prove that the productive phase of AI has begun. Three companies show how technology translates into competitive advantages and robust margins: Bayer, WashTec, and Volkswagen.
Read
Commented by Fabian Lorenz on December 15th, 2025 | 07:25 CET
Alarm bells ringing at Evotec! BioNTech and Vidac Pharma achieve success in the fight against cancer! Analysts recommend buying!
Alarm bells are ringing at Evotec. A major shareholder has completely withdrawn from the German biotech company. The security is trading at 2016 levels. Vidac Pharma, on the other hand, has reached a milestone. In the EU, the Phase 2b clinical trial for the ointment Tuvatexib (VDA1102) against a particularly active, fast-growing precursor of skin cancer can begin. BioNTech is also continuing the fight against cancer. Initial results from the global Phase 2 trial of the non-specific antibody candidate Pumitamig showed encouraging anti-tumor activity in advanced triple-negative breast cancer. Analysts recommend buying shares in Vidac and BioNTech.
Read
Commented by Stefan Feulner on December 15th, 2025 | 07:00 CET
Alibaba, Power Metallic Mines, Bayer – Spectacular twists
The 2025 stock market year is drawing to a close, and the major indices are likely to finish in positive territory once again. Nevertheless, fears of a correction are growing, especially for hyped AI stocks. In addition, due to sector rotation, there are companies that could stage a year-end rally due to their favorable valuations. Stock picking is likely to be more in demand than ever in the coming months.
Read
Commented by Fabian Lorenz on December 12th, 2025 | 06:55 CET
Buy these stocks now?! Bayer, Gerresheimer, WashTec!
Bayer is undoubtedly one of the positive surprises of 2025 on the German stock market. Operations are running smoothly for the Leverkusen-based company, particularly in the pharmaceutical sector. And next year, the glyphosate disaster could also come to an end. Analysts have now raised their price target. WashTec shares are still at the beginning of an upward trend. Growth, improved margins, a dividend yield of 5%, and a share buyback program continue to argue in favor of buying the stock. Analysts share this opinion. Experts do not yet see the time as right to buy Gerresheimer shares. Although the stock appears to have bottomed out, investors are still advised to wait.
Read
Commented by Carsten Mainitz on December 11th, 2025 | 07:20 CET
On the winning side – now and in 2026: Antimony Resources and Bayer, crash at Evotec!
The year 2025 is drawing to a close. It is time to focus on stocks and investment themes that could offer attractive returns in 2026. Trends such as AI, defense, and robotics are expected to continue. Further involvement in the commodities sector also appears lucrative. Here, investors can find an exciting second-tier investment story in the still largely undiscovered Canadian company Antimony Resources. But opportunities also exist in the blue-chip segment. Bayer has established a solid foundation this year, and analysts have recently raised their price targets significantly. For heavily punished stocks like Evotec, a turnaround could also emerge next year.
Read